The optical phenomenon of invasive fungal ill health was 5.3% in the posaconazole radical and 9.0% in the fluconazole building block (p = 0.07). Most fungal infections were caused by invasive aspergillus, for which posaconazole was more effective (2.3% versus 7.0%, p = 0.006).
Posaconazole was also associated with fewer deaths due to invasive fungal infections (1% versus 4%, p = 0.046). Rates of treatment-related serious adverse events were similar (13% and 10%).
"Posaconazole should be considered an pick for prophylaxis in patients with severe graft-versus-host disease," Dr. Ullmann and his associates conclude.
A prospective experimentation, led by Dr. Oliver A. Cornely at the Body of Cologne water in Germany, compared safe treatments among neutropenic patients with acute myelogenous leukemia or the myelodysplastic symptom.
The learning took status between 2006 and 2007 at 89 centers. Trinity hundred four patients were randomized to posaconazole; 240 patients were randomized to fluconazole; and 58 to itraconazole. Each drug was administered as an oral pause: posaconazole (200 mg t.i.d.), fluconazole (400 mg q.d.) or itraconazole (Sporanox, Janssen, 200 mg b.i.d.).